Teva Canada Announces the Launch of (Pr)Teva-Tolterodine Tablets and (Pr)Teva-Tolterodine LA Extended Release Capsules, Generics of (Pr)Detrol® and (Pr)Detrol LA®

TORONTO, Jan. 6, 2016 /CNW/ - Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced that Health Canada has approved its application for the generic versions of PrDetrol® and PrDetrol LA®. These anticholinergic-antispasmodic agents are indicated for the symptomatic management of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence, or any combinations of these symptoms.

In Canada, PrDetrol® had annual sales of approximately $5.9 million and PrDetrol LA® had annual sales of approximately $32.9 million, based on IMS Brogan sales data as of October 2015. PrTeva-Tolterodine tablets and PrTeva-Tolterodine LA extended release capsules are available immediately in pharmacies across Canada.

"Overactive bladder can range from being a nuisance to a severe problem in a person's life, affecting the patient's quality of life," said Doug Sommerville, Senior Vice President and General Manager, Teva Canada Limited. "By bringing both formulations of this popular medicine to the market as a lower cost generic version, we endeavor to support both patients and payors with a more affordable bioequivalent product to the brand-name version."

According to The Canadian Continence Foundation, as many as 3.3 million Canadians – almost 10 per cent of the population – experience some form of urinary incontinence, of which overactive bladder is one type.i  While there are many potential causes, patients who suffer from symptoms related to urinary incontinence often report a change in their day-to-day activity as a result, and report feeling embarrassed, discouraged and frustrated.ii

About Teva Canada Limited

Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare solutions for 50 years, with nearly 200,000iii prescriptions filled with our products every day. Originally Novopharm Limited, Teva Canada specializes in the development, production and marketing of high-quality generic prescription pharmaceuticals and through our branded division, Teva Canada Innovation, focuses on a diverse line of innovative products in a variety of therapeutic areas. Teva Canada employs more than 1,300 individuals, markets more than 400iv products in Canada and is a subsidiary of Teva Pharmaceutical Industries Ltd., the world's largest generic drug maker. For more information, visit: www.tevacanada.com or www.tevamakesmedicines.ca.

About Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2014 amounted to $20.3 billion. For more information, visit www.tevapharm.com.

i The Canadian Continence Foundation. What is Urinary Incontinence?. http://www.canadiancontinence.ca/EN/what-is-urinary-incontinence.php.  Accessed December 2015. 
ii Ibid.
iii IMS Compuscript TRx MAT October 2015
iv IMS CD&H MAT October 2015

SOURCE Teva Canada Limited

Image with caption: "Teva-Tolterodine is available as 1 mg and 2 mg tablets in bottles† of 60 tablets. Teva-Tolterodine LA is available as 2 mg and 4 mg extended release capsules in bottles† of 100 capsules. †May not be exactly as shown (CNW Group/Teva Canada Limited)". Image available at: http://photos.newswire.ca/images/download/20151215_C6454_PHOTO_EN_564829.jpg



For further information: PR Contact: Teva Pharmaceutical Industries Ltd.: Denise Bradley, Sr. Vice President, Global Corporate Reputation, Teva Pharmaceuticals, p. +1.215.591.8974, denise.bradley@tevapharm.com

Organization Profile

Teva Canada Limited

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890